Professional Documents
Culture Documents
Abbreviations 274
1. Background 274
2. Objectives 275
3. Scope 276
4. Glossary 278
5. Quality management system requirements for national
regulatory authorities 279
5.1 Quality management system concepts 279
5.2 Quality management system requirements 282
6. Quality management system implementation methodology 304
6.1 Supporting factors for quality management system implementation 304
6.2 Situational analysis of quality management system implementation status
in the national regulatory authority 305
6.3 Gap analysis for developing a roadmap for quality management system
implementation 307
6.4 Quality management system development and implementation roadmap 317
6.5 Activity plan for quality management system implementation 318
References 318
Appendix 1 References to the WHO Global Benchmarking Tool, revision VI 320
Appendix 2 Activity plan for quality management system implementation 323
273
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
Abbreviations
CREAM clear, relevant, economic, adequate and monitorable
EDQM European Directorate for the Quality of Medicines and
HealthCare
GBT WHO Global Benchmarking Tool (4)
GRP good regulatory practices
ICT information and communication technology
IT information technology
ISO International Organization for Standardization
M&E monitoring and evaluation
NRA national regulatory authority
PDCA plan–do–check–act
QA quality assurance
QMS quality management system
RCA root cause analysis
SMART specific, measurable, attainable, realistic and time-bound
SWOT strengths, weaknesses, opportunities and threats
WHO World Health Organization
1. Background
WHO Technical Report Series, No. 1025, 2020
Accordingly, to facilitate access to these products, WHO’s vision is for all Member
States to have an effective regulatory system that ensures medical products
and other health technologies in the market meet internationally recognized
standards of quality, safety and efficacy.
National regulatory authorities (NRAs) are responsible for ensuring the
safety, quality and efficacy of medical products within their respective Member
States; demonstrating that the services they provide consistently meet legal and
regulatory requirements; delivering effective and efficient services; evaluating
performance; and making improvements. An effective quality management
system (QMS) can help to ensure that the products or services an NRA provides
consistently meet statutory and regulatory standards and meet customers’
expectations. A QMS provides opportunities to enhance customer satisfaction;
address context-associated risks and opportunities for continued improvement;
demonstrate conformity to specific QMS requirements; and assure the quality,
safety and efficacy of medical products.
In 2015, WHO developed and launched the WHO Global Benchmarking
Tool (GBT) (4). This tool assists WHO and regulators worldwide in evaluating
the maturity and performance of regulatory systems and related functions. The
GBT includes one indicator that assesses the NRA’s level of development with
respect to a QMS (4). Benchmarking results of low- and middle-income countries
indicate that the majority of NRAs need to establish and implement a QMS or,
if already established, enhance and maintain the QMS.
QMS implementation is challenging for NRAs, owing to the diversity
of NRA legal mandates and organizational structures; the different levels of
NRA development; and the number of regulatory functions that need to be
implemented. WHO has developed this guideline to respond to requests by
Member States for an international guideline on implementation of QMSs
by NRAs.
2. Objectives
The aim of this guideline is to assist NRAs to develop, implement and
improve their QMSs, based on principles from International Organization for
Standardization (ISO) document ISO 9001 standard requirements (5). It
provides recommendations on what NRAs should implement and maintain
under each QMS to effectively and efficiently support the execution of NRA
functions as mandated by national laws and regulations. The guideline is
expected to promote consistency in regulatory practices within and across
NRAs, to facilitate harmonization, mutual reliance and recognition mechanisms
among Member States.
Therefore, the objectives of the guideline are as listed next.
275
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
3. Scope
This is an overarching guideline that should be applied across all regulatory
functions and activities, including registration and marketing authorization;
vigilance; market surveillance and control; licensing establishments; regulatory
inspections; laboratory access and testing; clinical trials oversight; national lot
release; and others, as applicable to the implementing NRA. The guideline should
be implemented to cover all types and categories of medical products and other
health technologies under the responsibility of an implementing NRA. All other
existing or future guidelines for QMSs for specific regulatory functions will
complement this guideline.
The guideline can also be used for other regulatory activities that are
mandated by the national laws and regulations to ensure public health safety, by
assuring the quality, safety and effectiveness of medical products. This extends to
areas of medical products such as pricing, professional training and regulation, as
well as to other areas within the legislative mandates and functions of the NRA.
This guideline on QMS implementation can also be used for all models
of NRA. NRAs can be legally, organizationally and operationally structured as
follows:
WHO Technical Report Series, No. 1025, 2020
extent possible without affecting the effectiveness and efficiency of the NRA to
execute its functions.
4. Glossary
The definitions given below apply to the terms used in this guideline that are
not defined in existing WHO terms and definitions databases. They may have
different meanings in other contexts.
competence. Knowledge, skills and attitude required for successful work
performance.
correction. Any action that is taken to eliminate a nonconformity. However,
corrections do not address causes.
corrective actions. Steps that are taken to eliminate the causes of existing
nonconformities in order to prevent recurrence. The corrective action process
tries to ensure that existing nonconformities and potentially undesirable
situations do not happen again.
customer. A person or organization that could or does receive a product or a
service that is intended for or required by this person or organization. Customers
of an NRA include individuals or parties who receive or could receive and
use products and services that are provided and offered by the NRA. These
parties include the general public, patients, manufacturers, distributors, health
practitioners, researchers, the ministry of health and other individuals and
institutions that rely on the NRA’s products and services to make public health
decisions.
customer satisfaction. A customer’s perception of the degree to which the
customer’s expectations have been fulfilled. This relates to the expectations
WHO Technical Report Series, No. 1025, 2020
that different parties have of the NRA. The expectations include assurance
that safe, efficacious and high-quality medical products will be available under
the NRA mandate to regulate, and that the NRA will provide other products
such as guidelines, public reports and related regulatory services that meet the
expectations of different types of customers.
internal audit. An examination and assessment of all or part of a QMS with the
specific purpose of improvement. An internal audit should be conducted by an
independent (i.e. of the function to be audited) team of competent auditors as
designated by the management for this purpose.
process. A set of interrelated or interacting activities that use inputs to deliver an
intended result. In the context of NRAs, the production and service provision
processes should coincide with basic regulatory functions.
278
Annex 13
Fig. 1
Applied PDCA cycle
NRA: national regulatory authority; PDCA: plan–do–check–act;
QMS: quality management system.
WHO Technical Report Series, No. 1025, 2020
280
Annex 13
The scope of the QMS and context of the NRA are placed in the middle,
to provide the limitations to which the QMS should be implemented.
Leadership and management are centrally indicated, as they are
important requirements for effective QMS implementation. Top management
should commit and support all QMS processes, from planning up to acting for
continuous improvement.
Document and data management are centrally indicated, because they
should be part of every step of the PDCA cycle, in the form of procedures, forms
and records that facilitate the consistent implementation of QMS processes and
record retention.
Applying risk-based approaches (included in planning stages) enables
NRAs to identify factors that could cause QMS processes to deviate or that
could prevent the planned results from being achieved; to put in place proactive
measures and controls to minimize the impact of negative effects; and to leverage
opportunities as they arise. Risk-based thinking is applicable and should be
implemented throughout the PDCA cycle.
NRAs should implement a QMS that identifies and integrates other
management system standards that are applicable to the processes. The
management systems that are for specific areas and processes should be
documented. The NRA should ensure that the management systems do not
create duplications, overlaps or inconsistencies within the overall QMS. While
other WHO guidelines have been implemented for management systems of
specific regulatory functions such as inspections and quality control testing, the
overall QMS should be consistently implemented throughout the organization
across different regulatory functions and other supporting areas.
QMSs are influenced by the different policies, objectives, diverse work
methods, resource availability and administrative practices specific to each
NRA. NRAs are free to decide the mode and routes to use when implementing
this guideline, as long as the implemented QMS yields effective, consistent,
transparent and reliable results in the regulation of medical products.
The QMS requirements that are described in this guideline are based
upon the quality management principles presented next, as provided in ISO
9000 (7).
282
Annex 13
Table A13.1
Summary of quality management system requirements for each subsection
283
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
5.2.1 Introduction
NRAs should have documented, available and accessible legislative laws and
regulatory policies on medical products that describe the regulatory functions
and activities that should be included in the QMS.
NRAs should list and maintain current versions and copies of national,
regional and international management system standards and guidelines that are
used for the QMS implementation.
NRAs should document the history and evolution of their QMS, to
demonstrate the controls and management of changes in the system to ensure
284
Annex 13
that it is effective for the institution. The evolution and changes should be justified
and related to any changes to the adopted national, regional and/or international
management system standards and guidelines (e.g. the case of the Compendium
of quality management system (QMS) technical documents for harmonization of
medicine regulation in the East African Community (8)).
NRAs should ensure that all existing and already implemented
management systems are integrated in the QMS. The integration should ensure
that there are systematic, adequate and appropriate linkages between the overall
QMS and the management systems for specific technical or administrative
functions. The QMS should be integrated into the regulatory processes, to ensure
that it helps the NRA to achieve its legal mandates and functions.
The NRA should identify the functions and processes that are already
covered by other QMSs. This should be done to identify gaps and align specific
management systems with the overall QMS of the NRA as much as possible, to
ensure consistency and facilitate effective performance M&E. The management
systems for specific technical and administrative functions and processes are
described in the next subsections.
5.2.6 Planning
5.2.6.1 Quality management system planning
NRAs should plan and document how they will meet the needs and expectations
of their customers and stakeholders, as stipulated in the national laws and
regulations. The plan should include all technical and administrative functions,
WHO Technical Report Series, No. 1025, 2020
290
Annex 13
principles can be based on the WHO guidelines on quality risk management (9)
and the ISO 31000 standard (10).
291
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
5.2.7.2 Personnel
NRAs should determine, provide and document the personnel and their required
minimum competencies necessary for effective implementation of the QMS
and for effective operation and control of its processes. A focal person or lead
may be appointed to coordinate and monitor the implementation of the QMS at
appropriate levels and functions.
The competencies of all personnel should include a combination of
appropriate education, professional training, experience and behavioural attitude,
as deemed necessary by the NRA. Where the assigned personnel with defined
responsibilities and authorities do not have all the competencies, training plans
should be developed and implemented, with appropriate evaluation criteria for
acquired competencies.
For the purposes of consistency of the QMS, NRA training plans for the
rest of the technical and administrative personnel and functions should be based
on the competency framework or matrix and/or performance appraisal system
coordinated by human resources departments.
Records of evidence of an employee’s competence, including educational
diplomas or degrees; completion of training certificates; resumés; performance
reviews; licences; and other documents should be retained.
WHO Technical Report Series, No. 1025, 2020
(i.e. in use versus not in use) and plans for qualification, validation, calibration
and maintenance (as applicable):
■■ buildings and associated utilities;
■■ technical (e.g. inspection and testing equipment) and administrative
equipment (e.g. servers, computers, and printers), including
hardware and software;
■■ transportation and logistical resources; and
■■ ICT.
NRAs should determine, provide and maintain the human and physical
factors of the work environment necessary for the operation of technical and
administrative processes and activities within the context of the organizational
structure and national legislation. To the extent that it is practical, the
environment should address social, psychological and physical (i.e. workspace)
conditions to promote work–life balance. Depending on the activities of the
NRA, applicable occupational, health and safety policies and procedures should
be considered for implementation, as provided in ISO 45001 (11).
The NRA and its units should implement and document a policy and
procedure on the management of waste that is generated. The waste management
should be conducted within the recommendations and applicable requirements
of the current version of ISO 14001 (12).
5.2.8 Operation
NRAs should ensure that planning of technical and administrative processes is
done effectively, as provided under Section 5.2.6 for all operations within the
scope of the QMS.
and services. The details of the regulatory products and services offered, including
contingency requirements (such as those applied during natural disasters or
epidemics), should be publicised (e.g. through the NRA website, pre-submission
meetings, or scientific advice), so that customers are aware of the requirements
for submissions to the NRA relating to regulatory products and services.
NRAs should ensure that the requirements and expectations for the
products and services are determined and defined within the applicable national
laws and regulations. To promote public transparency and accountability, the
product and service requirements may include fee schedules and delivery
timelines for product market authorizations, licences, reference standards (e.g.
pharmacopoeia), permits and certificates. This information may be included in
the national guidelines and guidance notes and should be publicly available to
customers and stakeholders.
NRAs should ensure through a review process that requests for
services received from customers are complete and in conformity with service
requirements. A checklist used for such reviews should be documented. When
there is a difference between the requirements for products or services as
requested by the customer and the requirements prescribed by the NRA, this
should be communicated to the customer and resolved before processing the
request. Any verbal request or change in the requirements, either by the NRA or
by the customer, should be confirmed before services are processed.
When the requirements for products and services are changed for any
reason, NRAs should take measures to inform all relevant interested parties.
They should retain evidence of the results of the revisions to the requirements of
products and services, and any new requirements for the products and services
that are provided.
procurements. However, the NRA should ensure that the public procurement
procedure conforms to the requirements described in the subsequent paragraphs
of this subsection and should close gaps, if any. The NRA should also implement
these requirements when it performs direct procurement.
NRAs should ensure that competence criteria are defined, documented
and implemented for the evaluation, selection, performance monitoring and
re‑evaluation of external providers and suppliers (e.g. NRAs having documented,
well-defined and transparent criteria for the selection and performance
monitoring of external non-staff experts).
When NRAs must perform in-house prequalification of providers,
there should be a documented procedure and policy on the competence criteria
for evaluation, selection, performance monitoring, and requalification. The
prequalification and requalification should focus on the competence of the
individual persons and the institution or company to provide the products and/
or services that meet applicable QMS requirements.
NRAs should implement measures for ensuring that the externally
provided products and services do not adversely affect the organization’s image
and ability to consistently deliver the products and services to the customers.
The NRA should determine which specific controls are to be implemented
for an external provider, and for incoming products and services provided by
them. Control activities that may be considered include inspections, certificates
of analysis or testing, second party audits, evaluation of statistical data and key
performance indicators.
The NRA should clearly communicate the requirements and controls to
be applied to the external provider, and both parties should agree as to what is
required. This understanding of requirements is usually reflected in a technical
service agreement, or through a purchase order or contract. The NRA should
ensure that the requirements communicated to the external providers are
complete and clear and address any potential issues.
there are adequate controls for those activities that are involved
in providing conforming products and services. For this purpose,
the following guidelines should be considered for adoption and
implementation, as applicable and to the extent necessary:
–– for technical processes involving review of application
documents for marketing authorization for the assurance of
quality, safety and efficacy, procedures and recommendations
this includes, among others: Good review practices: guidelines for
national and regional regulatory authorities (13); Regulation and
licensing of biological products in countries with newly developing
regulatory authorities (14) and WHO guidelines on evaluation of
similar biotherapeutic products (SBPs) (15);
–– where the NRA has a unit responsible for good practices
inspections, recommendations and technical requirements:
WHO Quality management systems requirements for national
inspectorates (16);
■■ as required, monitoring and measuring resources and equipment
should be available and in use, to ensure that the processes are
effective and controlled. Where measuring equipment must be
used in providing regulatory services of the NRA laboratory,
technical requirements and recommendations from the following
guidelines should be considered for adoption and implementation,
as applicable and to the extent necessary:
–– WHO good practices for pharmaceutical quality control
laboratories (17) for physicochemical testing and WHO good
practices for pharmaceutical microbiology laboratories (18) for
microbiological testing. These two WHO guidelines can be
supported and complemented with the current ISO/IEC 17025
WHO Technical Report Series, No. 1025, 2020
(e.g. characteristics of processes, products, services and potential risks) and the
methods to be used for monitoring, measurement, analysis and evaluation of
the performance and effectiveness of the QMS. The monitoring, measurement,
analysis and evaluation of the NRA performance should be linked to the
planned key performance indicators (or simply indicators), as applicable. The
establishment and implementation of the indicators should be as practical
as possible, to ensure that value is added through monitoring, measurement,
analysis and evaluation activities. Therefore, the indicators or key performance
indicators should have clear, relevant, economic, adequate and monitorable
(CREAM) attributes. NRAs should determine and document the frequency of
M&E of the indicators, from the implemented action and activity plans, as well
as from the performance and evaluation of the QMS. NRAs should ensure that
the M&E framework is consistent across different units, levels and functions of
the organization. The framework should be documented and aligned with the
relevant quality objectives (strategic objectives) of the NRA.
Table A13.2
Inputs and outputs for review meetings
302
Annex 13
5.2.10 Improvement
There are different methods to conduct improvement, such as correcting existing
nonconformities and deviations and taking actions to prevent recurrence, or
conducting ongoing, small-step improvement activities based on opportunities
identified either through risk analyses or breakthrough projects. These
improvement activities can lead to innovation, revision and/or improvement of
existing processes, or to the implementation of new processes.
NRAs should implement and document measures to record and react to
nonconformances and deviations by taking actions to control and correct them,
including with related plans for managing related activities, if any. In addition,
NRAs should conduct a root cause analysis (RCA) and evaluate the need to
act in order to avoid recurrence of the nonconformances and deviations in the
affected area, as well as in any similar processes in the organization in which
such nonconformances or deviations could occur. The steps involved in this
process are:
■■ reviewing and analysing the nonconformance or deviation;
■■ determining, to the extent possible, the cause(s) of the
nonconformance or deviation; and
■■ determining whether similar nonconformances exist or could
potentially occur within the affected unit or function and/or other
units of the NRA or functions that have similar processes.
After implementing the corrective action, NRAs should review and
document the effectiveness of the corrective action taken through practical
303
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
means, including during future internal audits that look for a recurrence of the
same nonconformity. The results of the RCA and the implemented corrective
actions should be used to update the risk and opportunity planning, as applicable.
Where corrective actions lead to changes to the process(es), NRAs should plan
for similar changes to the QMS, supported by a defined change management
plan. NRAs should define the communication of reports on nonconformances
and corrective actions to internal and external customers, as defined in the
communication policy/procedures.
For technical and administrative processes, NRAs should ensure
that the handling of nonconformances, deviations and corrective actions is
consistent across the entire organization. Nonconformances and deviations that
are related to professional misconduct of NRA personnel should be handled
in accordance with conditions of employment and service, including related
national legal provisions.
Improvement can include actions to reduce process variation; increase
the consistency of process outputs, products and services; and improve process
capability. This should be done to enhance the NRA’s performance and give
benefits to its customers and stakeholders. The results from performance
monitoring and evaluation and management reviews should be used to decide
which continual improvement actions should be implemented and what
resources and support should be provided for their implementation by top
management.
Full commitment of the head of the NRA and the heads of technical, support
and administrative units (i.e. top management) is necessary for effective
implementation and maintenance of the QMS in NRAs. This commitment
should be supported by demonstrating leadership, management, commitment
and customer focus through all stages of the implementation of the QMS.
The QMS should be designed to be integrated in regulatory processes (i.e. not
standalone); supported with adequate resources (human, financial, equipment
and infrastructure); and created to be simple enough to remain manageable with
the available resources, while being effective enough to support consistency,
effectiveness and efficiency.
Potential mechanisms that can support QMS implementation include:
■■ establishing effective coordination and communication mechanisms;
304
Annex 13
307
308
WHO Technical Report Series, No. 1025, 2020
Table A13.3
Guideline Existing system Stage 1 (non-existing QMS) Stage 2 (existing QMS Stage 3 (ineffective
section without implementation) implementation of QMS)
Guideline Existing system Stage 1 (non-existing QMS) Stage 2 (existing QMS Stage 3 (ineffective
section without implementation) implementation of QMS)
5.2.3 Adequate description NRAs should review and identify NRAs should review the NRAs should review the
Organizational and mandates of NRAs in gaps in the consistency of planning reports and contribution of QMS
context of the terms of: how issues for planning are records from different documents in making the
NRA • ability to define internal determined among different units, to identify gaps in planning more effective
and external issues units of the organization. QMS implementation of QMS and efficient to identify
and customers and documents should be developed documents. Where gaps gaps. Identified gaps
stakeholders and implemented to establish are identified, RCA should should be addressed by
consistency. be performed to ensure implementing changes to
that procedures are QMS documents.
implemented.
Annex 13
309
310
WHO Technical Report Series, No. 1025, 2020
Guideline Existing system Stage 1 (non-existing QMS) Stage 2 (existing QMS Stage 3 (ineffective
section without implementation) implementation of QMS)
Annex 13
certificates, others
311
312
WHO Technical Report Series, No. 1025, 2020
Guideline Existing system Stage 1 (non-existing QMS) Stage 2 (existing QMS Stage 3 (ineffective
section without implementation) implementation of QMS)
Annex 13
313
314
WHO Technical Report Series, No. 1025, 2020
Guideline Existing system Stage 1 (non-existing QMS) Stage 2 (existing QMS Stage 3 (ineffective
section without implementation) implementation of QMS)
Annex 13
315
316
WHO Technical Report Series, No. 1025, 2020
HR: human resources; ICT: information and communication technology; IT: information technology; M&E: monitoring and evaluation; NRA: national regulatory authority;
QMS: quality management system; RCA: root cause analysis; SOP: standard operating procedure.
Annex 13
Table A13.4
Development of quality management system implementation roadmap
317
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
References
1. Thirteenth General Programme of Work 2019–2023. Promote health, keep the world safe, serve
the vulnerable. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/bitstream/
handle/10665/324775/WHO-PRP-18.1-eng.pdf, accessed 4 November 2019).
2. World Health Organization. Leadership priorities (https://www.who.int/about/resources_planning/
WHO_GPW12_leadership_priorities.pdf, accessed 12 November 2019).
3. Resolution WHA67.20. Regulatory system strengthening for medical products. In: Sixty-seventh
World Health Assembly, Geneva, 19–23 May 2014. Geneva: World Health Organization; 2014
(http://apps.who.int/medicinedocs/documents/s21456en/s21456en.pdf, accessed 12 November
2019).
4. World Health Organization. Essential medicines and health products. WHO Global Benchmarking
Tool (GBT) for evaluation of national regulatory systems (https://www.who.int/medicines/
regulation/benchmarking_tool/en/, accessed 15 November 2019).
5. ISO 9001:2015(en). Quality management systems – requirements (https://www.iso.org/obp/
ui/#iso:std:iso:9001:ed-5:v1:en, accessed 5 November 2019).
6. Good regulatory practices: guidelines for national regulatory authorities for medical products.
Working document QAS/16.686. Geneva: World Health Organization; 2016 (https://www.who.int/
medicines/areas/quality_safety/quality_assurance/GoodRegulatory_PracticesPublicConsult.pdf,
accessed 12 November 2019).
7. ISO 9000:2015(en). Quality management systems – fundamentals and vocabulary (https://www.
iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en, accessed 12 November 2019).
8. Compendium of quality management system (QMS) technical documents for harmonization of
WHO Technical Report Series, No. 1025, 2020
medicine regulation in the East African Community. Arusha: East African Community Secretariat;
2014 (EAC/TF-MED/QMS/FD/COM/N1R0; http://apps.who.int/medicinedocs/documents/
s22311en/s22311en.pdf, accessed 12 November 2019).
9. WHO guidelines on quality risk management. In: WHO Expert Committee on Specifications for
Pharmaceutical Preparations: forty-seventh report: Annex 2. Geneva: World Health Organization;
2013 (WHO Technical Report Series, No. 981; https://www.who.int/medicines/areas/quality_
safety/quality_assurance/Annex2TRS-981.pdf, accessed 12 November 2019).
10. ISO 31000:2018(en). Risk management – guidelines (https://www.iso.org/obp/ui/#iso:std:
iso:31000:ed-2:v1:en, accessed 12 November 2019).
11. ISO 45001:2018(en) Occupational health and safety management systems – requirements
with guidance for use (https://www.iso.org/obp/ui/#iso:std:iso:45001:ed-1:v1:en, accessed 12
November 2019).
12. ISO 14001:2015(en). Environmental management systems – requirement with guidance for use
(https://www.iso.org/obp/ui/#iso:std:iso:14001:ed-3:v1:en, accessed 12 November 2019).
318
Annex 13
13. Good review practices: guidelines for national and regional regulatory authorities. In: WHO
Expert Committee on Specifications for Pharmaceutical Preparations: forty-ninth report: Annex 9.
Geneva: World Health Organization; 2015 (WHO Technical Report Series, No. 992; https://www.
who.int/medicines/areas/quality_safety/quality_assurance/Annex9-TRS992.pdf?ua=1, accessed
12 November 2019).
14. Regulation and licensing of biological products in countries with newly developing regulatory
authorities. In: WHO Expert Committee on Biological Standardization: forty-fifth report: Annex 1.
Geneva: World Health Organization; 1995 (WHO Technical Report Series, No. 858; https://www.
who.int/biologicals/publications/trs/areas/vaccines/regulatory/WHO_TRS_858_A1.pdf?ua=1,
accessed 12 November 2019).
15. WHO guidelines on evaluation of similar biotherapeutic products (SBPs). In: WHO Expert
Committee on Biological Standardization: sixtieth report: Annex 2. Geneva: World Health
Organization; 2013 (WHO Technical Report Series, No. 977; https://www.who.int/biologicals/
publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1, accessed 12
November 2019).
16. Quality management systems requirements for national inspectorates. In: WHO Expert
Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report: Annex 5.
Geneva: World Health Organization; 2020 (WHO Technical Report Series, No. 1025xxx ).
17. WHO good practices for pharmaceutical quality control laboratories. In: WHO Expert Committee
on Specifications for Pharmaceutical Preparations: forty-fourth report: Annex 1. Geneva: World
Health Organization; 2010 (WHO Technical Report Series, No. 957; https://www.who.int/
medicines/areas/quality_safety/quality_assurance/GoodpracticesPharmaceuticalQualityControl
LaboratoriesTRS957Annex1.pdf, accessed 12 November 2019).
18. WHO good practices for pharmaceutical microbiology laboratories. In: WHO Expert Committee
on Specifications for Pharmaceutical Preparations: forty-fifth report: Annex 2. Geneva: World
Health Organization; 2011 (WHO Technical Report Series, No. 961; http://apps.who.int/
medicinedocs/documents/s18682en/s18682en.pdf, accessed 12 November 2019).
19. ISO/IEC 17025. General requirements for the competence of testing and calibration laboratories.
Geneva: International Organisation for Standardisation; 2017 (https://www.iso.org/files/live/
sites/isoorg/files/store/en/PUB100424.pdf, accessed 12 November 2019).
20. Council of Europe. European Directorate for the Quality of Medicines and HealthCare. Quality
management (QM) documents (https://www.edqm.eu/en/quality-management-guidelines-86.
html, accessed 12 November 2019).
21. ISO 19011:2018(en). Guidelines for auditing management systems (https://www.iso.org/obp/
ui/#iso:std:iso:19011:ed-3:v1:en, accessed 13 November 2019).
319
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
Appendix 1
References to the WHO Global Benchmarking Tool,
revision VI
The WHO Global Benchmarking Tool (GBT) (4) is used to assess the level of
implementation of a quality management system (QMS) in a national regulatory
authority (NRA). The QMS indicator, RS05, consists of 14 subindicators that
are used to identify the degree of QMS implementation and the existing gaps
across the NRA.
320
Annex 13
Table continued
Subsection in QMS GBT VI – QMS Related GBT VI subindicators (4)
guideline subindicators (4)
5.2.5 Document RS05.07 RS01.04, RS01.05, RS01.08, RS09.06, RS09.08
and data VL03.04, VL04.01, VL04.02, VL04.03
management MA03.04, MA04.01, MA04.02, MA04.03,
MA04.10, MA05.02, MA06.01
MC03.04, MC04.01, MC04.02, MC04.03,
MC04.05, MC04.07, MC04.08, MC05.01,
MC05.02
LI03.04, LI04.01, LI05.01, LI06.01
RI03.04, RI04.01, RI04.02, RI04.04, RI04.05,
RI04.06, RI05.01, RI05.02
LT03.02, LT03.04, LT04.04, LT06.02, LT06.03,
LT08.01
CT03.04, CT04.05, CT04.06, CT04.07,
CT06.01
LR01.02, LR03.04, LR04.03
5.2.6 Planning RS05.02 RS03.03, RS04.05
VL04.04, VL04.08
MA01.12, MA04.06, MA04.07, MA06.02
MC04.04, MC05.03
LI04.03, LI05.02
RI04.03, RI05.05
LT03.01, LT08.04
CT06.02, CT06.04
LR06.04
5.2.7 Support and RS05.04, RS05.14 RS02.02, RS06.01, RS06.02, RS08.01, RS08.02,
resources RS08.03, RS09.03, RS09.07, RS09.09
VL02.02, VL03.01, VL03.02, VL03.03, VL06.01,
VL06.02, VL06.03
MA02.02, MA03.01, MA03.03, MA05.01,
MA05.03, MA05.04
MC02.02, MC03.01, MC03.03, MC06.01,
MC06.02, MC06.03
LI02.02, LI03.01, LI03.03, LI06.02
RI02.02, RI03.01, RI03.03, RI06.01, RI06.02,
RI06.03, RI06.04
LT03.03, LT04.01, LT04.03, LT05.01, LT05.02,
LT06.05, LT07.01, LT09.01, LT09.02, LT09.03
CT02.02, CT03.01, CT03.03, CT05.02
LR02.02, LR03.01, LR03.03, LR05.01, LR05.02,
LR06.01
321
WHO Expert Committee on Specifications for Pharmaceutical Preparations Fifty-fourth report
Table continued
Subsection in QMS GBT VI – QMS Related GBT VI subindicators (4)
guideline subindicators (4)
5.2.8 Operation RS05.06, RS05.09 RS02.03, RS04.02, RS04.03, RS06.03,
RS06.04, RS09.05, RS09.07
VL04.05, VL04.06, VL04.07
MA01.09, MA01.10, MA01.11, MA01.13,
MA04.05, MA04.08, MA04.09, MA04.10
MC01.06, MC01.07
LI01.04, LI04.02, LI04.04
RI01.04, RI05.03
LT02.02, LT06.01, LT06.04, LT10.01
CT01.09, CT01.10, CT04.01, CT04.02,
CT04.03, CT05.01
LR04.01, LR04.02
5.2.9 Performance RS05.10, RS05.11, RS01.09, RS10.01, RS10.02
evaluation RS05.12, RS05.13 VL05.02
MA04.06, MA06.02
MC04.06, MC05.03
LI05.02
RI05.04, RI05.05
LT08.02, LT08.03, LT08.04
CT06.02, CT06.04
LR06.02, LR06.04
5.2.10 Improvement RS05.05 LR06.02
GBT: WHO Global Benchmarking Tool (4); NRA: national regulatory authority; QMS: quality management system.
WHO Technical Report Series, No. 1025, 2020
322
Appendix 2
Activity plan for quality management system implementation
Step Activity Subsection Recommendations of documents Responsibility
of QMS and records to be established within the NRA
guideline
1. Appointment of QMS focal 5.2.4.3 Official letters of appointment with defined Head of the NRA
person(s) or lead(s) responsibilities and authorities in the QMS
2. QMS focal person(s) 5.2.7.2 • Competency matrix for QMS focal person(s)/ Top management
understands the QMS lead(s)
requirements • Training plans for competency gaps in QMS
implementation
• Training records of QMS focal person(s)/lead(s)
• Training/orientation records in development
and implementation of QMS documents (quality
manual, standard operating procedures and/or
forms and templates)
3. QMS focal person(s)/lead(s) 6.1 • Documented gap or situation analysis report • Top management
conducts a gap analysis of • Documented roadmap with resources, timelines • QMS focal
the current system based on and responsibilities (part of NRA strategic and person(s)/ lead(s)
Tables A13.3 and A13.4 of action plans)
the guideline and develops
Annex 13
a QMS action plan (as part of
the strategic plan)
323
324
WHO Technical Report Series, No. 1025, 2020
Annex 13
325
326
WHO Technical Report Series, No. 1025, 2020
Annex 13
IT: information technology; M&E: monitoring and evaluation; NRA: national regulatory authority; QMS: quality management system; SMART: specific, measurable, attainable,
realistic and time-bound; SWOT: strengths, weaknesses, opportunities and threats.
327